title: [Erythropoietic protein supportive treatment in small cell lung cancer].
abstract: Anemia is common among patients with malignant tumors, due to the disease and chemotherapy. Anemia decreases patient's quality of life, and worsens the dose intensity of chemotherapy. The aim of this retrospective data-analysis was to determine the rate of transfusions and the maintenance of chemotherapeutic dose intensity in 9 small cell lung cancer patients receiving beta-erythropoietin, due to anemia observed after the first cycle of chemotherapy. The mean pre-treatment hemoglobin concentration of the patients was 116.67+/-8.17 g/L (mean+/-SD). The mean pre-erythropoietin hemoglobin concentration at baseline was 103.11+/-7.52 g/L. Six cycles of platinum compounds and etoposide were used. The post-treatment hemoglobin concentration of patients was 110.11+/-5.37 g/L (p = 0,028 vs. baseline). During these 54 chemotherapeutic cycles, only 2 patients needed transfusion, each of them once. According to our experience, the use of beta-erythropoietin in 9 anemic small cell lung cancer patients resulted in a low rate of transfusions and maintenance of cytotoxic treatment dose intensity. The adequate use of beta-erythropoietin is of great help to the physician in the management of small cell lung cancer patients.
authors.affiliation: Semmelweis Egyetem, Pulmonológiai Klinika, Budapest. tamasi@pulm.sote.hu
authors.forename: Lilla
authors.initials: L
authors.lastname: Tamási
authors.forename: Veronika
authors.initials: V
authors.lastname: Müller
authors.forename: Pál
authors.initials: P
authors.lastname: Magyar
authors.forename: György
authors.initials: G
authors.lastname: Losonczy
mesh_terms: D000368:Aged; D000740:Anemia / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy* / Q000209:etiology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D016190:Carboplatin / Q000009:adverse effects; D018288:Carcinoma, Small Cell / Q000150:complications* / Q000188:drug therapy; D002945:Cisplatin / Q000009:adverse effects; D004921:Erythropoietin / Q000627:therapeutic use*; D005047:Etoposide / Q000009:adverse effects; D005260:Female; D006397:Hematinics / Q000627:therapeutic use*; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D008175:Lung Neoplasms / Q000150:complications* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D006397:Hematinics; D006454:Hemoglobins; D004921:Erythropoietin; D005047:Etoposide; D016190:Carboplatin; D002945:Cisplatin